Predicting outcome and therapy responses
Approximately thirty percent of all stage III melanoma patients will progress and develop distant metastases. Currently no markers exist that may identify stage III patients of high risk of relapse that would benefit from adjuvant therapy. Likewise, there is a lack of markers able to predict whether stage IV patients will respond to immune therapy or targeted treatment. In a recently funded project from Helse SØ we intend to characterize the tumor microenvironment combined with molecular profiling and ex vivo assessment of drug responses in attempts to provide information that either may stratify the patients for treatment.